SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 07/01/09 -- Theravance, Inc. (NASDAQ: THRX)
today reported that equity awards were made to three new employees.
Pursuant to Nasdaq Marketplace Rule 4350(i)(1)(A)(iv), the equity awards
were granted under the Theravance, Inc. 2008 New Employee Equity Incentive
Plan, which the Board of Directors of Theravance adopted to facilitate the
granting of equity awards to new employees. In accordance with Nasdaq
rules, these grants were made under an equity incentive plan without
stockholder approval. Nasdaq rules require a public announcement of equity
awards to be made under this type of plan. Three employees were granted
options to purchase an aggregate of 90,000 shares of the Company's common
stock, which options vest over four years and expire in 10 years assuming
continued employment. No officers received any award under this plan. The
exercise price for the option shares granted is $15.19, which was the
closing price of Theravance common stock on the Nasdaq Global Market as
such price was reported by NASDAQ on the date of grant.
About Theravance
Theravance is a biopharmaceutical company with a pipeline of internally
discovered product candidates. Theravance is focused on the discovery,
development and commercialization of small molecule medicines across a
number of therapeutic areas including respiratory disease, bacterial
infections and gastrointestinal motility dysfunction. The company's key
programs include: telavancin for the treatment of serious Gram-positive
bacterial infections with Astellas Pharma Inc. and the Horizon program and
Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program with
GlaxoSmithKline plc. By leveraging its proprietary insight of multivalency
toward drug discovery focused primarily on validated targets, Theravance is
pursuing a next generation strategy designed to discover superior medicines
in areas of significant unmet medical need. For more information, please
visit the company's web site at www.theravance.com.
THERAVANCE®, the Theravance logo, and MEDICINES THAT MAKE A DIFFERENCE®
are registered trademarks of Theravance, Inc.
Contact Information:
Michael W. Aguiar
Senior Vice President and Chief Financial Officer
650-808-4100
Email Contact